2011 Top 100: Pharmaceuticals
Pfizer Inc.
In 2010, Pfizer Inc. reported record sales of $67.8 billion, driven by an increasingly diverse portfolio of products. Growth within its Biopharmaceutical unit, as well as its Animal Health, Consumer Healthcare, Nutrition and Capsugel units, was largely driven by the addition of Wyeth’s products, like Advil, Centrum, Robitussin and ChapStick. Pfizer’s pending acquisition of Ferrosan’s consumer healthcare business, which is principally comprised of dietary supplement products, will further strengthen Pfizer’s consumer healthcare market share.
In 2010, Pfizer Inc. reported record sales of $67.8 billion, driven by an increasingly diverse portfolio of products. Growth within its Biopharmaceutical unit, as well as its Animal Health, Consumer Healthcare, Nutrition and Capsugel units, was largely driven by the addition of Wyeth’s products, like Advil, Centrum, Robitussin and ChapStick. Pfizer’s pending acquisition of Ferrosan’s consumer healthcare business, which is principally comprised of dietary supplement products, will further strengthen Pfizer’s consumer healthcare market share.